{"id":56467,"date":"2023-05-02T23:05:48","date_gmt":"2023-05-02T21:05:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/"},"modified":"2023-05-02T23:05:48","modified_gmt":"2023-05-02T21:05:48","slug":"iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/","title":{"rendered":"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting"},"content":{"rendered":"
\n

\nBoth leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors<\/i><\/p>\n

\nCompany reminds shareholders to vote today to protect the value of their investment and ensure Aurinia\u2019s continued momentum<\/i><\/p>\n

\nCompany to release first quarter financial and operational results on May 4, 2023<\/i><\/p>\n

\nShareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at assistance@laurelhill.com<\/a><\/i><\/p>\n

EDMONTON, Alberta–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (\u201cAurinia\u201d or the \u201cCompany\u201d) today announced that leading independent proxy advisor Institutional Shareholder Services (\u201cISS\u201d) has recommended that Aurinia shareholders vote FOR <\/b>the re-election of all eight incumbent directors to the Board of Directors (the \u201cBoard\u201d) at the Company\u2019s 2023 Annual General Meeting (the \u201cMeeting\u201d).<\/p>\n

<\/a><\/p>\n

\nISS\u2019 positive recommendation follows an April 26 report from Glass Lewis, another leading independent proxy advisor, which also recommended that shareholders vote for the re-election of all incumbent directors.<\/p>\n

\nAurinia is pleased that ISS and Glass Lewis recognize the Board and management\u2019s pivotal role in the Company\u2019s continued growth and momentum. Aurinia\u2019s Board also appreciates the feedback and continued strong support of our shareholders.<\/p>\n

\nAurinia\u2019s Board and management are taking the right steps to maximize shareholder value.<\/b><\/p>\n

\nAurinia is well-positioned for significant value enhancement. The Company continues to build upon its robust sales growth \u2013 with net sales increasing over 194% in 2022 \u2013 and is making significant progress in expanding LUPKYNIS\u2019 availability in international markets in partnership with Otsuka.<\/p>\n

\nIn 2022, LUPKYNIS received approvals in the UK and EU and launched in several EU countries. Our efforts to gain regulatory approval in Japan remain on track, and we continue to expect a PMDA submission in the back half of 2023. We believe that our commercialization efforts will continue to unlock significant value for shareholders.<\/p>\n

\nEach member of the Board has played an integral role in our progress to date. Our directors have the expertise needed to oversee and guide management and drive continued growth, including the commercialization of pharmaceutical and biotech products, business development, and international pharmaceutical operations. They also bring strong track records of value creation and commercial success.<\/p>\n

\nAurinia\u2019s executive compensation aligns pay with performance.<\/b><\/p>\n

\nAurinia disagrees with ISS\u2019 recommendation regarding the Company\u2019s advisory vote on executive compensation. Our Compensation Committee, which is comprised entirely of independent directors, makes all compensation decisions while leveraging advice from an independent third-party compensation consultant. The Compensation Committee conducts a rigorous and thorough review of market practices, especially those of peers, the general marketplace and other industry data points to determine performance targets, pay mix and levels that will best align management\u2019s interests with those of shareholders and support continued value creation. Aurinia has also engaged extensively with its shareholder base each year since the 2021 AGM and has made several improvements to the compensation program to incorporate feedback from shareholders, as detailed on page 54 of the proxy statement.<\/p>\n

\nImportantly, ISS recognized that annual incentives for Aurinia executives were based largely on the achievement of pre-set corporate objectives, with the CEO’s bonus being based solely on such goals. Aurinia has also previously announced that it will add a performance component to Long-Term Incentive Plan awards in 2023.<\/p>\n

\nThe Company also notes that leading proxy advisor Glass Lewis recommended shareholders vote \u201cFOR\u201d Aurinia\u2019s say-on-pay resolution, along with all other proposals. We will continue to listen to shareholder feedback regarding our executive compensation and other important matters.<\/p>\n

\nAURINIA SHAREHOLDERS: PROTECT THE VALUE OF YOUR INVESTMENT BY VOTING ONLINE, BY MAIL, OR TELEPHONE TODAY.<\/b><\/p>\n

\nTo ensure Aurinia\u2019s continued momentum at a pivotal time for the Company, the Board encourages all shareholders to vote \u201cFOR\u201d ALL<\/b> proposals today.<\/p>\n

\nThe virtual-only meeting will be held via live audio webcast online using the LUMI meeting platform at https:\/\/web.lumiagm.com\/467056294<\/a> (password (case sensitive): aurinia2023) on Wednesday, May 17, 2023 at 12:00 pm, Eastern Time.<\/p>\n

\nCompany to Report First Quarter 2023 Financial and Operational Results on May 4, 2023<\/b><\/p>\n

\nAs previously announced<\/a>, Aurinia will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023, before markets open. Aurinia\u2019s management team will host a conference call\/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 (Toll-free U.S. & Canada). The audio webcast can also be accessed under “News\/Events\u201d through the \u201cInvestors\u201d section of the Aurinia corporate website at www.auriniapharma.com<\/a>. A replay of the webcast will be available on Aurinia\u2019s website.<\/p>\n

\nQuestions or Require Voting Assistance?<\/b><\/p>\n

\nContact our proxy solicitation agent, Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at assistance@laurelhill.com<\/a>.<\/p>\n

\nAbout LUPKYNIS<\/b><\/p>\n

\nLUPKYNIS\u00ae<\/sup> is the first U.S. FDA- and EC-approved oral medicine for the treatment of adult patients with active LN. LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia\u2019s proprietary personalized eGFR-based dosing protocol. Boxed Warning, warnings, and precautions for LUPKYNIS are consistent with those of other CNI-immunosuppressive treatments.<\/p>\n

\nAbout Aurinia<\/b><\/p>\n

\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS\u00ae<\/sup> (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company\u2019s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor\/Media Contact:<\/b>
Aurinia@westwicke.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia\u2019s continued momentum Company to release first quarter financial and operational results on May 4, 2023 Shareholders with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56467","6":"format-standard","7":"category-industry"},"yoast_head":"\nISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia\u2019s continued momentum Company to release first quarter financial and operational results on May 4, 2023 Shareholders with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T21:05:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230502006216\/en\/1781617\/21\/aurina_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting\",\"datePublished\":\"2023-05-02T21:05:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/\"},\"wordCount\":1009,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006216\\\/en\\\/1781617\\\/21\\\/aurina_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/\",\"name\":\"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006216\\\/en\\\/1781617\\\/21\\\/aurina_logo.jpg\",\"datePublished\":\"2023-05-02T21:05:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006216\\\/en\\\/1781617\\\/21\\\/aurina_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006216\\\/en\\\/1781617\\\/21\\\/aurina_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/","og_locale":"en_US","og_type":"article","og_title":"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting - Pharma Trend","og_description":"Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia\u2019s continued momentum Company to release first quarter financial and operational results on May 4, 2023 Shareholders with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-02T21:05:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230502006216\/en\/1781617\/21\/aurina_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting","datePublished":"2023-05-02T21:05:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/"},"wordCount":1009,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502006216\/en\/1781617\/21\/aurina_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/","url":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/","name":"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502006216\/en\/1781617\/21\/aurina_logo.jpg","datePublished":"2023-05-02T21:05:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230502006216\/en\/1781617\/21\/aurina_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230502006216\/en\/1781617\/21\/aurina_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote \u201cFOR\u201d ALL Company Director Nominees at 2023 Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56467"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56467\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}